ClassID:

109181

C12N2310/3341 - page 3 - CPC Classification

Classification description:

Structure or type of the nucleic acid; Chemical structure of the base; Modified C 5-Methylcytosine

Recent Application in this class:
#601
20180092990
2018-04-05

Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof

#602
20180087052
2018-03-29

Modulation of huntingtin expression

#603
20180073022
2018-03-15

Modulation of alpha synuclein expression

#604
20180066256
2018-03-08

RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders

#605
20180051283
2018-02-22

Compositions and methods for modulating Tau expression

#606
20180051282
2018-02-22

ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF

#607
20180044676
2018-02-15

Compositions and methods for modulating TTR expression

#608
20180044673
2018-02-15

METHODS FOR MODULATING MECP2 EXPRESSION

#609
20180030450
2018-02-01

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

#610
20180030444
2018-02-01

Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers

#611
20180023085
2018-01-25

IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE

#612
20180023077
2018-01-25

Compositions for modulating expression of C9ORF72 antisense transcript

#613
20180010128
2018-01-11

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#614
20180009837
2018-01-11

Compounds and methods for the modulation of proteins

#615
20180002701
2018-01-04

Antisense oligonucleotides for modulating HTRA1 expression

#616
20180002697
2018-01-04

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#617
20180002695
2018-01-04

COMPOUNDS AND METHODS FOR IMPROVED CELLULAR UPTAKE OF ANTISENSE COMPOUNDS

#618
20180002693
2018-01-04

COMPOSITIONS AND METHODS

#619
20170369883
2017-12-28

MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

#620
20170369875
2017-12-28

EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

#621
20170369872
2017-12-28

REVERSIR TM COMPOUNDS

#622
20170363643
2017-12-21

Methods for treating spinal muscular atrophy

#623
20170362596
2017-12-21

Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition

#624
20170355986
2017-12-14

ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION

#625
20170355727
2017-12-14

Conjugated antisense compounds and their use

#626
20170349897
2017-12-07

Compositions for modulating C9ORF72 expression

#627
20170335329
2017-11-23

ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF

#628
20170321216
2017-11-09

Modulation of AGPAT5 expression

#629
20170314026
2017-11-02

Modulation of prekallikrein (PKK) expression

#630
20170283804
2017-10-05

ANTISENSE COMPOUNDS AND USES THEREOF

#631
20170275620
2017-09-28

MODULATION OF APOLIPOPROTEIN C-III EXPRESSION

#632
20170268006
2017-09-21

TOLL-LIKE RECEPTOR 9 ANTAGONIST AND METHODS OF USE THEREOF

#633
20170268002
2017-09-21

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#634
20170253880
2017-09-07

Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field

#635
20170247702
2017-08-31

PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders

#636
20170247695
2017-08-31

ISOTOPOLOGUES OF SMAD7 ANTISENSE OLIGONUCLEOTIDES

#637
20170240893
2017-08-24

Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide

#638
20170240892
2017-08-24

Polynucleotide agents targeting Serpinc1 (AT3) and methods of use thereof

#639
20170240891
2017-08-24

MicroRNA compounds and methods for modulating miR-21 activity

#640
20170233741
2017-08-17

IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE

#641
20170233732
2017-08-17

MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS

#642
20170204418
2017-07-20

Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof

#643
20170191064
2017-07-06

Oligonucleotides for inducing paternal UBE3A expression

#644
20170183661
2017-06-29

Compositions and methods for modulating PKK expression

#645
20170182082
2017-06-29

Antisense compounds

#646
20170175116
2017-06-22

Compositions and methods for decreasing tau expression

#647
20170175114
2017-06-22

Compositions for modulating Ataxin 2 expression

#648
20170175113
2017-06-22

Methods for modulating Ataxin 2 expression

#649
20170166899
2017-06-15

Compositions and methods for modulating growth hormone receptor expression

#650
20170166895
2017-06-15

Nucleic acid compounds for binding to complement component 3 protein

#651
20170159055
2017-06-08

Compositions and methods for modulating complement factor B expression

#652
20170145424
2017-05-25

COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS

#653
20170145413
2017-05-25

Cancer treatment

#654
20170145409
2017-05-25

Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom

#655
20170137811
2017-05-18

Targeting microRNAS for the treatment of liver cancer

#656
20170136131
2017-05-18

Alternative nucleic acid molecules and uses thereof

#657
20170136055
2017-05-18

Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof

#658
20170121710
2017-05-04

Methods and compositions for modulating apolipoprotein (a) expression

#659
20170073689
2017-03-16

MODULATORS OF GROWTH HORMONE RECEPTOR

#660
20170073688
2017-03-16

Modulation of TMPRSS6 expression

#661
20170067056
2017-03-09

RNA interference in dermal and fibrotic indications

#662
20170043037
2017-02-16

RNA containing modified nucleosides and methods of use thereof

#663
20170037410
2017-02-09

Compositions for modulating SOD-1 expression

#664
20170037409
2017-02-09

MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION

#665
20170037403
2017-02-09

OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS

#666
20170037402
2017-02-09

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#667
20170035798
2017-02-09

MODULATION OF FACTOR 11 EXPRESSION

#668
20170029818
2017-02-02

RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy

#669
20170022501
2017-01-26

METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)

#670
20170015997
2017-01-19

Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer

#671
20170009239
2017-01-12

RNA interference in skin indications

#672
20170009238
2017-01-12

System of interdependent anticancer antisense oligonucleotides targeting mRNAs the targets of which are NADPH-dependent, combined with one or more inhibitors of the Pentose Phosphate Pathway to deplete NADPH

#673
20170009237
2017-01-12

Short interfering RNA (siRNA) analogues

#674
20170002359
2017-01-05

Modulation of prekallikrein (PKK) expression

#675
20160369275
2016-12-22

Modulation of transthyretin expression

#676
20160369273
2016-12-22

Compositions and their uses directed to huntingtin

#677
20160362687
2016-12-15

Methods and compositions for modulating alpha-1 antitrypsin expression

#678
20160355820
2016-12-08

Aptamer construct

#679
20160348104
2016-12-01

Modulation of signal transducer and activator of transcription 3 (STAT3) expression

#680
20160319281
2016-11-03

Multiplex guide RNAs

#681
20160312225
2016-10-27

Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response

#682
20160312217
2016-10-27

Modulation of huntingtin expression

#683
20160304877
2016-10-20

COMPOUNDS AND METHODS FOR MODULATION OF DYSTROPHIA MYOTONICA-PROTEIN KINASE (DMPK) EXPRESSION

#684
20160304876
2016-10-20

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

#685
20160304871
2016-10-20

Compositions for modulating C9ORF72 expression

#686
20160298121
2016-10-13

Targeted augmentation of nuclear gene output

#687
20160298099
2016-10-13

PERMANENT GENE CORRECTION BY MEANS OF NUCLEOTIDE-MODIFIED MESSENGER RNA

#688
20160264975
2016-09-15

Modified nucleosides, nucleotides, and nucleic acids, and uses thereof

#689
20160251655
2016-09-01

Compositions for modulating C9ORF72 expression

#690
20160244768
2016-08-25

Method for reducing circulating leukocytes in a human subject

#691
20160244765
2016-08-25

Reduced size self-delivering RNAI compounds

#692
20160244753
2016-08-25

MicroRNA compounds and methods for modulating miR-21 activity

#693
20160237437
2016-08-18

Toll-like receptor 9 antagonist and methods of use thereof

#694
20160237434
2016-08-18

Modulation of apolipoprotein C-III expression

#695
20160237432
2016-08-18

METHODS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT

#696
20160230172
2016-08-11

COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT

#697
20160222389
2016-08-04

MODULATORS OF COMPLEMENT FACTOR B

#698
20160208258
2016-07-21

miR-92 inhibitors and uses thereof

#699
20160201060
2016-07-14

Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response

#700
20160194349
2016-07-07

Compositions and methods for modulating angiopoietin-like 3 expression

#701
20160177307
2016-06-23

PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders

#702
20160177306
2016-06-23

Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field

#703
20160152974
2016-06-02

Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile

#704
20160145617
2016-05-26

Compositions for modulating Tau expression

#705
20160122761
2016-05-05

COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS

#706
20160108397
2016-04-21

Targeting microRNAs for the treatment of fibrosis

#707
20160108396
2016-04-21

OLIGOMERS TARGETING HEXANUCLEOTIDE REPEAT EXPANSION IN HUMAN C9ORF72 GENE

#708
20160090598
2016-03-31

Antisense compounds and uses thereof

#709
20160090596
2016-03-31

Compositions and methods for modulating apolipoprotein (a) expression

#710
20160090595
2016-03-31

Compositions and methods for modulating apolipoprotein C-III expression

#711
20160076032
2016-03-17

Compositions and methods

#712
20160076031
2016-03-17

Phosphorous-linked oligomeric compounds and their use in gene modulation

#713
20160076030
2016-03-17

Compositions and methods for modulating HBV expression

#714
20160076027
2016-03-17

Compositions and methods for modulation nucleic acids through nonsense mediated decay

#715
20160068846
2016-03-10

Modulation of androgen receptor expression

#716
20160068845
2016-03-10

Modulation of dystrophia myotonica-protein kinase (DMPK) expression

#717
20160060626
2016-03-03

MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION

#718
20160053256
2016-02-25

COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN

#719
20160046945
2016-02-18

Modulation of hepatitis B virus (HBV) expression

#720
20160046941
2016-02-18

Targeting microRNAs for the treatment of liver cancer

#721
20160040163
2016-02-11

DNAI FOR THE MODULATION OF GENES

#722
20160032289
2016-02-04

Oral delivery of therapeutically effective LNA oligonucleotides

#723
20160032286
2016-02-04

Inhibitors of MYH7B and uses thereof

#724
20160032285
2016-02-04

Compositions and methods for modulating Tau expression

#725
20160024496
2016-01-28

Methods for monitoring C9ORF72 expression

#726
20160017329
2016-01-21

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#727
20160010093
2016-01-14

Oligomers and oligomer conjugates

#728
20160002637
2016-01-07

Multiple exon skipping compositions for DMD

#729
20160002634
2016-01-07

Multiple exon skipping compositions for DMD

#730
20160002633
2016-01-07

Multiple exon skipping compositions for DMD

#731
20160002632
2016-01-07

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#732
20160002631
2016-01-07

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#733
20160002628
2016-01-07

METHODS AND COMPOSITIONS FOR MANAGING VASCULAR CONDITIONS

#734
20160002625
2016-01-07

Cancer treatment

#735
20150376625
2015-12-31

Selective antisense compounds and uses thereof

#736
20150376623
2015-12-31

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

#737
20150376618
2015-12-31

Multiple exon skipping compositions for DMD

#738
20150376617
2015-12-31

Multiple exon skipping compositions for DMD

#739
20150376616
2015-12-31

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#740
20150376615
2015-12-31

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#741
20150376614
2015-12-31

Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations

#742
20150361428
2015-12-17

EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY

#743
20150353931
2015-12-10

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#744
20150337312
2015-11-26

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

#745
20150337305
2015-11-26

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#746
20150337304
2015-11-26

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#747
20150337303
2015-11-26

Methods and compositions for modulating apolipoprotein (a) expression

#748
20150322429
2015-11-12

SNPs OF APOLIPOPROTEIN B AND MODULATION OF THEIR EXPRESSION

#749
20150322428
2015-11-12

COMPOUNDS AND METHODS FOR IMPROVED CELLULAR UPTAKE OF ANTISENSE COMPOUNDS

#750
20150315596
2015-11-05

Antisense modulation of PTP1B expression

#751
20150315594
2015-11-05

Compositions and methods for modulating angiopoietin-like 3 expression

#752
20150315585
2015-11-05

Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers

#753
20150315573
2015-11-05

Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

#754
20150315572
2015-11-05

RNA preparations comprising purified modified RNA for reprogramming cells

#755
20150307877
2015-10-29

Compositions and their uses directed to huntingtin

#756
20150299703
2015-10-22

In vivo gene silencing by chemically modified and stable siRNA

#757
20150299699
2015-10-22

MICROMIRs

#758
20150297629
2015-10-22

MODULATION OF RENIN-ANGIOTENSIN SYSTEM (RAS) RELATED DISEASES BY ANGIOTENSINOGEN

#759
20150291960
2015-10-15

MODULATION OF CD40 EXPRESSION

#760
20150291955
2015-10-15

Antisense compounds targeting genes associated with fibronectin

#761
20150284725
2015-10-08

Methods of treating kennedy's disease

#762
20150275216
2015-10-01

Methods and compositions for inhibition of immune responses and autoimmunity

#763
20150275205
2015-10-01

Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome

#764
20150267197
2015-09-24

Methods for modulating C9ORF72 expression

#765
20150259679
2015-09-17

Compositions for modulating C9ORF72 expression

#766
20150218558
2015-08-06

MicroRNA compounds and methods for modulating miR-21 activity

#767
20150211011
2015-07-30

Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field

#768
20150191723
2015-07-09

Modulation of UBE3A-ATS expression

#769
20150184164
2015-07-02

ANTISENSE MODULATION OF FIBROBLAST GROWTH FACTOR RECEPTOR 4 EXPRESSION

#770
20150184156
2015-07-02

MODULATION OF APOLIPOPROTEIN (a) EXPRESSION

#771
20150176007
2015-06-25

Compositions and methods for modulating HBV expression

#772
20150176005
2015-06-25

Modulation of enhancer RNA mediated gene expression

#773
20150167008
2015-06-18

Antisense modulation of superoxide dismutase 1, soluble expression

#774
20150167004
2015-06-18

OLIGONUCLEOTIDE INHIBITORS OF DNA METHYLTRANSFERASES AND THEIR USE IN TREATING DISEASES

#775
20150164936
2015-06-18

Methods and compositions for the inhibition of gene expression

#776
20150159155
2015-06-11

Modulation of huntingtin expression

#777
20150152411
2015-06-04

METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION

#778
20150148404
2015-05-28

RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders

#779
20150141493
2015-05-21

Antisense modulation of GCCR expression

#780
20150133528
2015-05-14

Compositions and methods for modulating hemoglobin gene family expression

#781
20150126720
2015-05-07

Compositions and methods for modulating apolipoprotein (a) expression

#782
20150126719
2015-05-07

Compositions and methods for modulating apolipoprotein C-III expression

#783
20150126718
2015-05-07

Conjugated antisense compounds and their use

#784
20150099792
2015-04-09

Antisense modulation of GCGR expression

#785
20150087691
2015-03-26

Methods and compositions for modulating alpha-1-antitrypsin expression

#786
20150064725
2015-03-05

Engineered nucleic acids and methods of use thereof

#787
20150038558
2015-02-05

RNA containing modified nucleosides and methods of use thereof

#788
20150031747
2015-01-29

METHODS AND COMPOSITIONS FOR MODULATING FACTOR VII EXPRESSION

#789
20140378533
2014-12-25

MODULATION OF RNA BY REPEAT TARGETING

#790
20140377868
2014-12-25

RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci

#791
20140371296
2014-12-18

Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1 (MALAT-1) expression

#792
20140357701
2014-12-04

Modulation of hepatitis B virus (HBV) expression

#793
20140343123
2014-11-20

Conjugated antisense compounds and their use

#794
20140336370
2014-11-13

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#795
20140336237
2014-11-13

Modulation of signal transducer and activator of transcription 3 (STAT3) expression

#796
20140329882
2014-11-06

Oligomeric compounds and compositions for use in modulation of small non-coding RNAS

#797
20140323707
2014-10-30

Selective antisense compounds and uses thereof

#798
20140316121
2014-10-23

Methods and compounds useful in conditions related to repeat expansion

#799
20140309286
2014-10-16

Modulation of TMPRSS6 expression

#800
20140309279
2014-10-16

Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and uses thereof

#801
20140301982
2014-10-09

Complement antagonists and uses thereof

#802
20140275215
2014-09-18

Anti-clusterin monotherapy for cancer treatment

#803
20140275214
2014-09-18

Custirsen treatment with reduced toxicity

#804
20140243389
2014-08-28

Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof

#805
20140242192
2014-08-28

Clusterin antisense therapy for treatment of cancer

#806
20140235844
2014-08-21

Short interfering RNA (siRNA) analogues

#807
20140235694
2014-08-21

Antisense modulation of PTP1B expression

#808
20140228300
2014-08-14

Methods for modulating factor 12 expression

#809
20140213631
2014-07-31

Methods for modulating kallikrein (KLKB1) expression

#810
20140206854
2014-07-24

Targeting microRNAs for the treatment of liver cancer

#811
20140193825
2014-07-10

Modulation of angiopoietin-like 3 expression

#812
20140193396
2014-07-10

Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response

#813
20140187610
2014-07-03

Connective tissue growth factor antisense oligonucleotides

#814
20140142163
2014-05-22

Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field

#815
20140114057
2014-04-24

Antisense compounds targeting genes associated with usher syndrome

#816
20140113950
2014-04-24

RNA interference in dermal and fibrotic indications

#817
20140107184
2014-04-17

Modulation of hepatitis B virus (HBV) expression

#818
20140107180
2014-04-17

Modulation of androgen receptor expression

#819
20140100261
2014-04-10

TRPM-2 antisense therapy

#820
20140080892
2014-03-20

Antisense modulation of fibroblast growth factor receptor 4 expression

#821
20140057963
2014-02-27

Oligomeric compounds and compositions for use in modulation of small non-coding RNAS

#822
20140005252
2014-01-02

Modulation of alpha synuclein expression

#823
20130331434
2013-12-12

Methods for modulating factor 12 expression

#824
20130317085
2013-11-28

Modulation of apolipoprotein C-III expression

#825
20130289093
2013-10-31

MicroRNA compounds and methods for modulating miR-21 activity

#826
20130289092
2013-10-31

Compounds and methods for modulating interaction between proteins and target nucleic acids

#827
20130281684
2013-10-24

Compositions and their uses directed to huntingtin

#828
20130281509
2013-10-24

Antisense modulation of fibroblast growth factor receptor 4 expression

#829
20130245099
2013-09-19

Antagonat compositions and methods of use

#830
20130197068
2013-08-01

RNA containing modified nucleosides and methods of use thereof

#831
20130190380
2013-07-25

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

#832
20130189782
2013-07-25

Compositions and their uses directed to huntingtin

#833
20130174286
2013-07-04

In vivo gene silencing by chemically modified and stable siRNA

#834
20130131147
2013-05-23

Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom

#835
20130116301
2013-05-09

Antisense modulation of GCGR expression

#836
20130109091
2013-05-02

Compositions and methods for modulation of SMN2 splicing

#837
20130059777
2013-03-07

MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION

#838
20130053431
2013-02-28

Modulation of growth hormone receptor expression and insulin-like growth factor expression

#839
20130046007
2013-02-21

Selective reduction of allelic variants

#840
20130035366
2013-02-07

Modulation of Hepatitis B virus (HBV) expression

#841
20130030036
2013-01-31

Modulation of forkhead box O1A expression

#842
20130028889
2013-01-31

DOSING REGIMENS FOR TREATING AND PREVENTING OCULAR DISORDERS USING C-RAF ANTISENSE

#843
20130023579
2013-01-24

Modulation of angiopoietin-like 3 expression

#844
20120322851
2012-12-20

Oral delivery of therapeutically effective LNA oligonucleotides

#845
20120322850
2012-12-20

TRPM-2 antisense therapy

#846
20120322848
2012-12-20

LNA OLIGONUCLEOTIDES AND THE TREATMENT OF CANCER

#847
20120316221
2012-12-13

COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA

#848
20120316219
2012-12-13

MODULATION OF APOLIPOPROTEIN(A) EXPRESSION

#849
20120295962
2012-11-22

Targeting microRNAs for the treatment of liver cancer

#850
20120295961
2012-11-22

MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION

#851
20120295958
2012-11-22

Modulation of glucagon receptor expression

#852
20120295955
2012-11-22

RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3

#853
20120295272
2012-11-22

Proinflammatory nucleic acids

#854
20120289580
2012-11-15

Antisense modulation of PTP1B expression

#855
20120283319
2012-11-08

Method of inhibiting miR-33 using a modified oligonucleotide

#856
20120283312
2012-11-08

Modulation of eIF4E expression

#857
20120277284
2012-11-01

Modulation of signal transducer and activator of transcription 3 (STAT3)expression

#858
20120270929
2012-10-25

MODULATION OF TTC39 EXPRESSION TO INCREASE HDL

#859
20120270924
2012-10-25

Oligomeric compounds for the modulation of HIF-1A expression

#860
20120252879
2012-10-04

Modulation of huntingtin expression

#861
20120238937
2012-09-20

Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)

#862
20120237975
2012-09-20

ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF

#863
20120232125
2012-09-13

MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 1 EXPRESSION

#864
20120214865
2012-08-23

Methods for slowing familial ALS disease progression

#865
20120214862
2012-08-23

MODULATION OF FACTOR 7 EXPRESSION

#866
20120214736
2012-08-23

COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS

#867
20120202874
2012-08-09

Antisense oligonucleotide modulation of STAT3 expression

#868
20120196921
2012-08-02

MODULATION OF SGLT-2 EXPRESSION

#869
20120184031
2012-07-19

ANTISENSE INHIBITION VIA RNASE H-INDEPENDENT REDUCTION IN MRNA

#870
20120157514
2012-06-21

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#871
20120149755
2012-06-14

ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION

#872
20120149109
2012-06-14

MODULATION OF TRANSTHYRETIN EXPRESSION

#873
20120136043
2012-05-31

ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES THEREOF IN MEDICAL FIELD

#874
20120128699
2012-05-24

Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response

#875
20120122954
2012-05-17

Antisense oligomers targeting PCSK9

#876
20120122216
2012-05-17

Oligomeric compounds and compositions for use in modulation of small non-coding RNAs

#877
20120115932
2012-05-10

Modulation of STAT 6 expression

#878
20120115930
2012-05-10

COMPOSITIONS AND THEIR USES DIRECTED TO HEPCIDIN

#879
20120115926
2012-05-10

ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION

#880
20120088814
2012-04-12

METHODS OF MODULATING AN IMMUNE RESPONSE TO A VIRAL INFECTION

#881
20120083522
2012-04-05

MODULATION OF INFLAMMATORY RESPONSES BY FACTOR XI

#882
20120077866
2012-03-29

Antisense modulation of C-reactive protein expression

#883
20120077862
2012-03-29

Antisense modulation of PTP1B expression

#884
20120076781
2012-03-29

METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES

#885
20120053230
2012-03-01

Treatment of neurological disorders by dsRNA administration

#886
20120041050
2012-02-16

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#887
20120040459
2012-02-16

Reduced size self-delivering RNAi compounds

#888
20120035248
2012-02-09

Method for inhibiting the activity of mir-155

#889
20120029060
2012-02-02

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#890
20120029059
2012-02-02

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#891
20120029058
2012-02-02

Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof

#892
20120029057
2012-02-02

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#893
20120029049
2012-02-02

Antisense modulation of superoxide dismutase 1, soluble expression

#894
20120022145
2012-01-26

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#895
20120022144
2012-01-26

Antisense oligonucleotides for inducing exon skipping and methods of use thereof

#896
20120022133
2012-01-26

ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION

#897
20120004288
2012-01-05

COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION

#898
20120004276
2012-01-05

RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF EXPRESSION OF MITOCHONDRIAL GLYCEROL-3 PHOSPHATE ACYLTRANSFERASE 1 (MTGPAT1)

#899
20110319471
2011-12-29

LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR

#900
20110319469
2011-12-29

SNPs of apolipoprotein B and modulation of their expression